Financial health
- Operating income covered interest expense -37.0× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
LNAI Financials Lunai Bioworks Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $51992 | -$4M | 0.0% | -16729.4% | 39.5% | -35.8% | -$5M | — | $2M |
| 2025 | — | -$178M | — | — | 833.8% | -2162.7% | — | — | $92700 |
| 2024 | — | -$88M | — | — | -67.0% | -54.2% | -$11M | — | $220467 |
| 2023 | — | -$40M | — | — | -85.3% | -68.1% | -$12M | — | $2M |
| 2022 | — | -$113M | — | — | -156.2% | -134.0% | -$16M | — | $9M |
| 2021 | — | -$27M | — | — | -15.3% | -14.1% | -$21M | — | $21M |
| 2020 | — | -$11M | — | — | -6.9% | -6.4% | -$11M | — | $9M |
| 2019 | — | -$18M | — | — | -10.4% | -10.0% | -$9M | — | $12M |
| 2018 | — | -$6M | — | — | -4.0% | -3.5% | -$4M | — | $16M |
| 2017 | — | -$2M | — | — | -139.8% | -47.4% | — | — | $4M |
| 2016 | — | -$2M | — | — | 272.2% | -199.3% | — | $102882 | $23368 |
| 2014 | — | -$2M | — | — | -68.1% | -45.2% | — | $99951 | $3M |
| 2013 | $32768 | -$2M | -233.6% | -5306.8% | 127.5% | -476.7% | — | $728001 | $18794 |
| 2013 | — | -$95587 | — | — | 135.4% | -723.1% | — | — | — |
| 2013 | — | -$79181 | — | — | 146.1% | -589.2% | — | — | — |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $31050 | -$2M | 0.0% | -6888.6% | 22.3% | -20.2% | -$2M | — | $2M |
| Mar '26 | $20942 | -$3M | 100.0% | -7054.1% | 26.9% | -26.1% | -$1M | — | $3M |
| Dec '25 | — | -$2M | — | — | 13.3% | -27.0% | — | — | $491645 |
| Sep '25 | — | $3M | — | — | -21.6% | 40.5% | — | — | $624808 |
| Jun '25 | — | -$127M | — | — | 593.6% | -1539.7% | — | — | $92700 |
| Mar '25 | — | $189176 | — | — | 0.2% | 0.2% | — | — | $923002 |
| Dec '24 | — | -$7M | — | — | -8.8% | -6.5% | — | — | $311764 |
| Sep '24 | — | -$44M | — | — | -45.1% | -36.3% | — | — | $220571 |
| Jun '24 | — | -$16M | — | — | -11.9% | -9.6% | -$2M | — | $220467 |
| Mar '24 | — | -$59M | — | — | -43.9% | -33.1% | -$3M | — | $312697 |
| Dec '23 | — | -$5M | — | — | -10.4% | -7.8% | — | — | $243980 |
| Sep '23 | — | -$9M | — | — | -19.6% | -15.9% | — | — | $523474 |
| Jun '23 | — | -$23M | — | — | -49.9% | -39.8% | -$2M | — | $2M |
| Mar '23 | — | -$4M | — | — | -6.5% | -5.5% | -$3M | — | $3M |
| Dec '22 | — | -$4M | — | — | -6.7% | -5.6% | — | — | $4M |
| Sep '22 | — | -$8M | — | — | -10.9% | -9.3% | — | — | $8M |
| Jun '22 | — | -$90M | — | — | -124.3% | -106.6% | -$3M | — | $9M |
| Mar '22 | — | -$6M | — | — | -3.8% | -3.4% | -$3M | — | $11M |
| Dec '21 | — | -$7M | — | — | -4.0% | -3.6% | -$5M | — | $14M |
| Sep '21 | — | -$10M | — | — | -6.2% | -5.7% | -$5M | — | $15M |
Valuation over time
How the market has priced LNAI against its own fundamentals since 2025-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 319.5× (Jun '26) to 9.8× (Oct '26).
P/S
Frequently asked questions
Is LNAI growing its revenue and profit?
See the revenue and net-income charts above for Lunai Bioworks Inc.'s multi-year trend.
How much debt does LNAI have?
As of FY2026, Lunai Bioworks Inc. reported — of total debt against $2M of cash; operating income covered interest expense -37.0×.
What is LNAI's profit margin?
In FY2026, gross margin was —, operating margin -16729.4%, and net margin -6852.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.